NexImmune, Inc. (NEXI)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 28.16 Million USD | -55.35% |
| 2022 | 63.08 Million USD | 18.45% |
| 2021 | 53.25 Million USD | 91.21% |
| 2020 | 27.85 Million USD | 33.35% |
| 2019 | 20.88 Million USD | 57.71% |
| 2018 | 13.24 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 3.5 Billion USD | 32.8% |
| 2024 Q1 | 2.64 Million USD | -43.5% |
| 2023 Q4 | 4.67 Million USD | -53.21% |
| 2023 Q3 | 9.99 Million USD | 28.4% |
| 2023 Q1 | 9.82 Million USD | -43.03% |
| 2023 Q2 | 7.78 Million USD | -20.77% |
| 2023 FY | 28.16 Million USD | -55.35% |
| 2022 Q3 | 14.85 Million USD | -6.72% |
| 2022 Q2 | 15.92 Million USD | 5.8% |
| 2022 Q1 | 15.05 Million USD | -3.08% |
| 2022 FY | 63.08 Million USD | 18.45% |
| 2022 Q4 | 17.24 Million USD | 16.1% |
| 2021 Q1 | 10.07 Million USD | 42.82% |
| 2021 FY | 53.25 Million USD | 91.21% |
| 2021 Q4 | 15.53 Million USD | 0.27% |
| 2021 Q3 | 15.49 Million USD | 27.36% |
| 2021 Q2 | 12.16 Million USD | 20.78% |
| 2020 Q2 | 6.77 Million USD | 6.51% |
| 2020 Q1 | 6.36 Million USD | 23.08% |
| 2020 FY | 27.85 Million USD | 33.35% |
| 2020 Q4 | 7.05 Million USD | -8.02% |
| 2020 Q3 | 7.66 Million USD | 13.15% |
| 2019 Q4 | 5.16 Million USD | 0.0% |
| 2019 FY | 20.88 Million USD | 57.71% |
| 2018 FY | 13.24 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| America Great Health | 661.23 Thousand USD | -4159.853% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | -203.922% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | 6.086% |
| Biora Therapeutics, Inc. | 67.14 Million USD | 58.051% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -77.792% |
| Better Therapeutics, Inc. | 38.26 Million USD | 26.383% |
| Calithera Biosciences, Inc. | 40.68 Million USD | 30.774% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -127.291% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | 16.773% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | 18.163% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 74.031% |
| Evolutionary Genomics, Inc. | 992.8 Thousand USD | -2737.153% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | 13.567% |
| Galera Therapeutics, Inc. | 46.95 Million USD | 40.007% |
| Innovation1 Biotech Inc. | 1.21 Million USD | -2218.909% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -41.266% |
| Molecular Templates, Inc. | 63.09 Million USD | 55.354% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | -102.184% |
| Orgenesis Inc. | 45.75 Million USD | 38.441% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -9.828% |
| Point of Care Nano-Technology, Inc. | 73.41 Thousand USD | -38266.991% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -74.463% |
| Scopus BioPharma Inc. | 11.71 Million USD | -140.442% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 93.02% |
| Statera Biopharma, Inc. | 28.82 Million USD | 2.296% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -48.806% |
| Trevena, Inc. | 38.41 Million USD | 26.672% |
| Vaxxinity, Inc. | 56.05 Million USD | 49.747% |
| Vaccinex, Inc. | 23.45 Million USD | -20.092% |
| Vicapsys Life Sciences, Inc. | 1.04 Million USD | -2590.363% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | 44.435% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -287.202% |